Genfit SA
F:XUP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Genfit SA
F:XUP
|
FR |
|
P
|
Pharming Group NV
SWB:PHGN
|
NL |
|
C
|
Compagnie De l'odet SE
SWB:49F
|
FR |
|
L
|
LY Corp
DUS:YOJ
|
JP |
|
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
|
US |
|
S
|
Stef SA
F:STP
|
FR |
|
Majestic Gold Corp
XTSX:MJS
|
CA |
|
W
|
Wilmar International Ltd
OTC:WLMIY
|
SG |
|
S
|
Sumitomo Mitsui Financial Group Inc
F:XMF
|
JP |
|
F
|
Frontier Lithium Inc
OTC:LITOF
|
CA |
|
I
|
Industrial and Commercial Bank of China Ltd
F:ICK
|
CN |
|
Nongfu Spring Co Ltd
HKEX:9633
|
CN |
|
Diebold Nixdorf Inc
NYSE:DBD
|
US |
|
F
|
FIH Mobile Ltd
XMUN:FW3
|
TW |
|
E
|
Ethos Ltd
NSE:ETHOSLTD
|
IN |
|
Venus Concept Inc
NASDAQ:VERO
|
CA |
|
Strides Pharma Science Ltd
NSE:STAR
|
IN |
|
N
|
Norsk Hydro ASA
XHAM:NOH1
|
NO |
|
Schneider Electric SE
PAR:SU
|
FR |
|
A
|
Associated British Foods PLC
XMUN:AFO1
|
UK |
|
A
|
Allkem Ltd
XBER:3O10
|
AU |
|
A
|
AXA SA
PAR:CSNV
|
FR |
|
C
|
Constellation Brands Inc
XMUN:CB1A
|
US |
Genfit SA
Genfit SA is a biopharmaceutical company that develops medicines and diagnostic tools for liver diseases. Its main work has focused on conditions such as metabolic dysfunction-associated steatohepatitis, or MASH, and other serious liver disorders where doctors need better ways to identify patients and slow disease progression. The company does not sell a broad consumer product line; it builds drug candidates and disease tests for use in specialist medical settings. Genfit makes money mainly by advancing its own drug programs, licensing technology, and working with partners in drug development and diagnostics. In this kind of business, value comes from turning research into approved treatments or validated tests that can be sold to hospitals, labs, or pharmaceutical partners. It may also earn fees or milestone payments when partners use its intellectual property or help develop a product. What makes Genfit's business model different is that it sits at the point where liver disease research meets patient care. Many biotech companies focus only on drugs, but Genfit has also built expertise in diagnostic testing, which can help find the right patients for treatment and support clinical trials. That gives the company a role in both detecting disease and developing therapies for it.
Genfit SA is a biopharmaceutical company that develops medicines and diagnostic tools for liver diseases. Its main work has focused on conditions such as metabolic dysfunction-associated steatohepatitis, or MASH, and other serious liver disorders where doctors need better ways to identify patients and slow disease progression. The company does not sell a broad consumer product line; it builds drug candidates and disease tests for use in specialist medical settings.
Genfit makes money mainly by advancing its own drug programs, licensing technology, and working with partners in drug development and diagnostics. In this kind of business, value comes from turning research into approved treatments or validated tests that can be sold to hospitals, labs, or pharmaceutical partners. It may also earn fees or milestone payments when partners use its intellectual property or help develop a product.
What makes Genfit's business model different is that it sits at the point where liver disease research meets patient care. Many biotech companies focus only on drugs, but Genfit has also built expertise in diagnostic testing, which can help find the right patients for treatment and support clinical trials. That gives the company a role in both detecting disease and developing therapies for it.
